Filter sub products categories alphabetically
Rabeprazole belongs to the proton pump inhibitor class and treats heartburn, ulcers, and gastro-oesophageal reflux disease (GERD). The US FDA authorized it on August 19, 1999, to treat numerous gastrointestinal disorders. The therapy of symptomatic gastro-oesophageal reflux disease was approved on February 12, 2002. It is also used to treat diseases where the stomach generates excessive acid, such as Zollinger-Ellison syndrome in adults. Rabeprazole is also used in the treatment of ulcers. It works by lowering acid production in the stomach.
BRAND NAMES:
Aciphex – Aciphex contains Rabeprazole sodium as the active ingredient available in the market as Aciphex delayed-release tablets 20 mg.
Pariet – It is also available in the form of tablets with rabeprazole sodium as the main active ingredient.
MECHANISM OF ACTION:
Rabeprazole sodium works by inhibiting the proton pump within the stomach lining, which reduces gastric acid production. The function of the proton pump is also known as the H+/K+ ATPase enzyme. This enzyme is found in the stomach's parietal cells and is responsible for gastric acid production. The proton pump converts hydrogen ions (H+) from the parietal cells into potassium ions (K+) from the stomach lumen. Rabeprazole targets this proton pump directly. It is absorbed in the small intestine and transferred to parietal cells in inactive form. After reaching the acidic environment of the parietal cells, Rabeprazole sodium is protonated and converted into its active sulphonamide form. The activated form then covalently binds to cysteine residues on the H+/K+ATPase enzyme, inhibiting its activity. By blocking the enzyme, rabeprazole sodium prevents the secretion of hydrogen ions into the stomach, thereby reducing gastric acid production.
PHARMACOKINETICS:
Absorption: It takes 3 to 4 hours to achieve its maximum plasma concentration. The absolute bioavailability of oral administration is around 52%.
Metabolism: It passes through a comprehensive, mostly non-enzymatic metabolism, with the metabolites eliminated by the kidneys. CYP3A4 and CYP2C19 contribute to enzymatic metabolism
Excretion: 90% of the drug is eliminated through urine.
PHARMACODYNAMICS:
It lowers esophageal damage and stomach ulcers in people with gastro-oesophageal reflux disease by stopping the stomach from producing acid. The selective and irreversible proton pump inhibitor rabeprazole inhibits the production of stomach acid by specifically inhibiting H+, K+ -ATPase, which is present on the surface of parietal cells. It prevents hydrogen ions from entering the stomach lumen in their final state.
DOSAGE AND ADMINISTRATION:
Rabeprazole is available in the form of oral capsules and tablets
DRUG INTERACTIONS:
Before using rabeprazole it is required to discuss with the doctor the medications which have been used for another treatment. Taking rabeprazole with other medicines may interact and decrease the functioning of the drug and also cause some adverse effects. Below are some medicines which interact with the rabeprazole
FOOD INTERACTIONS:
Avoid smoking and alcohol as intake of alcohol leads to stomach acid thereby increasing acidity and heartburn.
ADVERSE EFFECTS:
TOXICITY:
Overdose of rabeprazole can cause some toxic effects.